Tirzepatide shows superior weight loss and glycemic control compared to Dulaglutide.
Guideline-Based Recommendations
Diagnosis
Assess cardiovascular risk in patients with type 2 diabetes.
Management
Consider GLP-1 receptor agonists like Tirzepatide or Dulaglutide for patients with type 2 diabetes and cardiovascular disease.
Monitoring & Follow-up
Regularly monitor blood glucose levels and cardiovascular health.
Risks
Monitor for gastrointestinal side effects and potential pancreatitis.
Patient & Prescribing Data
Tirzepatide is typically initiated at a dose of 2.5 mg once weekly, with potential escalation to 5 mg, 7.5 mg, or 10 mg based on tolerance and glycemic control.
Source for dose escalation information: Clinical trial data from SURPASS studies.
Clinical Best Practices
Individualize treatment based on patient preferences, comorbidities, and risk factors.
by Steven E. Nissen, Kathy Wolski, David D’Alessio, Govinda Weerakkody, Jacek Kiljanski, Russell J. Wiese, Imre Pavo, Bertrand Cariou, Stephen J. Nicholls
Advanced heart failure does not always present as a single defining event. Referring physicians may instead notice a pattern of worsening symptoms, recurrent hospitalizations or increasing difficulty maintaining a patient’s clinical stability.
